EN PL

EMEA: Guideline on the Clinical Investigation of Medicinal Products for the Treatment of Attention Deficit Hyperactivity Disorder (ADHD)

30.01.2009
EMEA:
Guideline on the Clinical Investigation of Medicinal Products for the Treatment of Attention Deficit Hyperactivity Disorder (ADHD). This Guideline is intended to assist applicants during the development of medicinal products intended for the treatment of attention deficit hyperactivity disorder (ADHD), independent of the class of product under investigation. It is only guidance; any deviation from guidelines should be explained and discussed in the Clinical Overview.